Trial Profile
A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary) ; Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Feb 2018 Planned End Date changed from 10 Apr 2018 to 1 Mar 2018.
- 10 Jan 2018 Planned End Date changed from 30 Dec 2017 to 10 Apr 2018.